The estimated Net Worth of L. Jeremy Stigall is at least $621 Tisíc dollars as of 6 March 2024. L Stigall owns over 8,889 units of ClearPoint Neuro Inc stock worth over $621,172 and over the last 2 years L sold CLPT stock worth over $0.
L has made over 1 trades of the ClearPoint Neuro Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently L exercised 8,889 units of CLPT stock worth $108,535 on 6 March 2024.
The largest trade L's ever made was exercising 8,889 units of ClearPoint Neuro Inc stock on 6 March 2024 worth over $108,535. On average, L trades about 556 units every 0 days since 2022. As of 6 March 2024 L still owns at least 50,874 units of ClearPoint Neuro Inc stock.
You can see the complete history of L Stigall stock trades at the bottom of the page.
L's mailing address filed with the SEC is C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100, SOLANA BEACH, CA, 92075.
Over the last 12 years, insiders at ClearPoint Neuro Inc have traded over $1,109,516 worth of ClearPoint Neuro Inc stock and bought 529,405 units worth $775,964 . The most active insiders traders include Lynnette C Fallon, Michael Pietrangelo a R John Fletcher. On average, ClearPoint Neuro Inc executives and independent directors trade stock every 93 days with the average trade being worth of $207,411. The most recent stock trade was executed by Lynnette C Fallon on 14 May 2024, trading 17,153 units of CLPT stock currently worth $209,438.
we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot
ClearPoint Neuro Inc executives and other stock owners filed with the SEC include: